2026-04-18T02:22:03Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/68812025-10-24T10:18:01Zcom_2072_378070com_2072_378040col_2072_378092

Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice Mariscal, Anaís Milán, Milena Baucells, Andrés Martínez, Maria Angeles Garcia Guillen, Andrea Trallero Araguas, Ernesto Alvarado-Cardenas, Marcelo Sanz Martinez, Maria Teresa Viñas Gimenez, Laura Selva O'Callaghan, Albert Institut Català de la Salut [Mariscal A, Baucells A, Martínez MA] Immunology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. [Milán M, Guillen AG] Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. [Trallero-Araguás E] Unitat de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Alvarado-Cardenas M] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Sanz-Martínez MT, Viñas-Giménez L] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Selva-O'Callaghan A] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain Vall d'Hebron Barcelona Hospital Campus Dermatomiositis - Diagnòstic Autoanticossos - Immunologia DISEASES::Musculoskeletal Diseases::Muscular Diseases::Myositis::Polymyositis::Dermatomyositis Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Autoantibodies Other subheadings::Other subheadings::Other subheadings::/immunology ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculares::miositis::polimiositis::dermatomiositis Otros calificadores::Otros calificadores::/diagnóstico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::autoanticuerpos Otros calificadores::Otros calificadores::Otros calificadores::/inmunología Càncer; Dermatomiositis; Immunoassaig Cáncer; Dermatomiositis; Inmunoensayo Cancer; Dermatomyositis; Immunoassay Objectives: Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. Methods: We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. Results: A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen’s kappa 0.3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16.5% Euroline vs 0.8% in-house immunoblot, p<0.01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0.0014 vs p=0.0502 for in-house immunoblot vs Euroline). Conclusion: We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method 2022-01-24T14:22:29Z 2022-01-24T14:22:29Z 2021-02-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Mariscal A, Milán M, Baucells A, Martínez MA, Guillen AG, Trallero-Araguás E, et al. Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot: Usefulness in Clinical Practice. Front Immunol. 2021 Feb 1;11:3672. 1664-3224 https://hdl.handle.net/11351/6881 10.3389/fimmu.2020.625896 33613568 000619602500001 http://hdl.handle.net/11351/6881 eng Frontiers in Immunology;11 https://doi.org/10.3389/fimmu.2020.625896 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Frontiers Media Scientia